SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aadi Bioscience, Inc. – ‘10-K’ for 12/31/23 – ‘EX-31.2’

On:  Wednesday, 3/13/24, at 4:19pm ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-10901   ·   File #:  1-38560

Previous ‘10-K’:  ‘10-K’ on 3/29/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   12 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/24  Aadi Bioscience, Inc.             10-K       12/31/23   81:12M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.98M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     41K 
 3: EX-21.1     Subsidiaries List                                   HTML     23K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     23K 
 9: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     44K 
                Awarded Compensation                                             
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
15: R1          Cover Page                                          HTML     91K 
16: R2          Audit Information                                   HTML     28K 
17: R3          Consolidated Balance Sheets                         HTML    118K 
18: R4          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
19: R5          Consolidated Statements of Operations and           HTML    105K 
                Comprehensive Loss                                               
20: R6          Consolidated Statements of Stockholders' Equity     HTML     81K 
21: R7          Consolidated Statements of Cash Flows               HTML    117K 
22: R8          Nature of Organization and Operations               HTML     32K 
23: R9          Summary of Significant Accounting Policies          HTML    105K 
24: R10         Fair Value Measurement                              HTML     60K 
25: R11         Short-Term Investments and Cash Equivalents         HTML     59K 
26: R12         Intangible Asset                                    HTML     32K 
27: R13         Accrued Liabilities                                 HTML     36K 
28: R14         Operating Leases                                    HTML     51K 
29: R15         License Agreements                                  HTML     32K 
30: R16         Stockholders' Equity                                HTML     36K 
31: R17         Share-Based Compensation                            HTML     76K 
32: R18         Employee Stock Purchase Plan                        HTML     34K 
33: R19         Income Taxes                                        HTML     66K 
34: R20         Commitments and Contingencies                       HTML     32K 
35: R21         Employee Retirement Plan                            HTML     29K 
36: R22         Summary of Significant Accounting Policies          HTML    123K 
                (Policies)                                                       
37: R23         Summary of Significant Accounting Policies          HTML     77K 
                (Tables)                                                         
38: R24         Fair Value Measurement (Tables)                     HTML     59K 
39: R25         Short-Term Investments and Cash Equivalents         HTML     62K 
                (Tables)                                                         
40: R26         Intangible Asset (Tables)                           HTML     29K 
41: R27         Accrued Liabilities (Tables)                        HTML     36K 
42: R28         Operating Leases (Tables)                           HTML     52K 
43: R29         Share-Based Compensation (Tables)                   HTML     66K 
44: R30         Employee Stock Purchase Plan (Tables)               HTML     31K 
45: R31         Income Taxes (Tables)                               HTML     60K 
46: R32         Nature of Organization and Operations (Detail)      HTML     56K 
47: R33         Summary of Significant Accounting Policies -        HTML     77K 
                Narrative (Detail)                                               
48: R34         Summary of Significant Accounting Policies -        HTML     32K 
                Schedule of Cash, Cash Equivalents and Restricted                
                Cash (Details)                                                   
49: R35         Summary of Significant Accounting Policies -        HTML     31K 
                Schedule of Inventory (Details)                                  
50: R36         Summary of Significant Accounting Policies -        HTML     45K 
                Property and Equipment (Details)                                 
51: R37         Summary of Significant Accounting Policies -        HTML     31K 
                Gross-to-Net Sales Adjustments (Details)                         
52: R38         Summary of Significant Accounting Policies -        HTML     33K 
                Schedule of Outstanding Potentially Dilutive                     
                Securities Excluded in Calculation of Diluted Net                
                Loss per Share (Detail)                                          
53: R39         Fair Value Measurement - Asset and Liabilities      HTML     76K 
                Measured on Recurring Basis (Details)                            
54: R40         Short-Term Investments and Cash Equivalents         HTML     52K 
                (Details)                                                        
55: R41         Intangible Asset - Narrative (Details)              HTML     34K 
56: R42         Intangible Asset - Schedule of Estimated            HTML     31K 
                Amortization Expense Related to Definite Lived                   
                Intangible Asset (Detail)                                        
57: R43         Accrued Liabilities - Schedule of Accrued           HTML     41K 
                Liabilities (Detail)                                             
58: R44         Operating Leases - Narrative (Detail)               HTML     37K 
59: R45         Operating Leases - Schedule of Information Related  HTML     33K 
                to Lease (Detail)                                                
60: R46         Operating Leases - Schedule of Rent Expense         HTML     27K 
                (Detail)                                                         
61: R47         Operating Leases - Schedule of Future Minimum       HTML     48K 
                Lease Payments Required under Operating Lease                    
                (Detail)                                                         
62: R48         License Agreements (Detail)                         HTML     63K 
63: R49         Stockholders' Equity (Detail)                       HTML     83K 
64: R50         Share-Based Compensation - Narrative (Detail)       HTML    103K 
65: R51         Share-Based Compensation - Schedule of Stock        HTML     71K 
                Option Activity (Detail)                                         
66: R52         Share-Based Compensation - Schedule of Recognized   HTML     58K 
                Compensation Cost Restricted Stock Units (Details)               
67: R53         Share-Based Compensation - Schedule of Recognized   HTML     30K 
                Compensation Cost Related to Employee and                        
                Non-employee Stock-Based Compensation Activity                   
                (Detail)                                                         
68: R54         Share-Based Compensation - Stock Options Valuation  HTML     48K 
                Assumptions (Detail)                                             
69: R55         Employee Stock Purchase Plan - Narrative (Details)  HTML     58K 
70: R56         Employee Stock Purchase Plan - Calculation          HTML     55K 
                Assumptions (Details)                                            
71: R57         Income Taxes - Narrative (Detail)                   HTML     46K 
72: R58         Income Taxes - Schedule of Reconciliation of        HTML     42K 
                Statutory Federal Income Tax (Detail)                            
73: R59         Income Taxes - Schedule of Significant Components   HTML     47K 
                of Deferred Tax Assets and Liabilities (Detail)                  
74: R60         Income Taxes - Schedule of Changes to Gross         HTML     30K 
                Unrecognized Tax Benefits (Detail)                               
75: R61         Commitments and Contingencies - Narrative (Detail)  HTML     35K 
76: R62         Employee Retirement Plan (Details)                  HTML     25K 
78: XML         IDEA XML File -- Filing Summary                      XML    140K 
81: XML         XBRL Instance -- aadi-20231231_htm                   XML   1.32M 
77: EXCEL       IDEA Workbook of Financial Report Info              XLSX    147K 
11: EX-101.CAL  XBRL Calculations -- aadi-20231231_cal               XML    178K 
12: EX-101.DEF  XBRL Definitions -- aadi-20231231_def                XML    524K 
13: EX-101.LAB  XBRL Labels -- aadi-20231231_lab                     XML   1.46M 
14: EX-101.PRE  XBRL Presentations -- aadi-20231231_pre              XML    934K 
10: EX-101.SCH  XBRL Schema -- aadi-20231231                         XSD    153K 
79: JSON        XBRL Instance as JSON Data -- MetaLinks              467±   704K 
80: ZIP         XBRL Zipped Folder -- 0001628280-24-010901-xbrl      Zip   2.59M 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Scott Giacobello, certify that:
1.I have reviewed this annual report on Form 10-K of Aadi Bioscience, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
By:/s/ Scott Giacobello
Scott Giacobello
Chief Financial Officer
(Principal Financial Officer)


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/13/248-K
For Period end:12/31/23
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/03/24  Aadi Bioscience, Inc.             424B5                  1:219K                                   Donnelley … Solutions/FA


11 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/02/23  Aadi Bioscience, Inc.             8-K:5,7,9   9/27/23   15:537K                                   Donnelley … Solutions/FA
 3/29/23  Aadi Bioscience, Inc.             10-K       12/31/22   92:31M                                    Workiva Inc Wde… FA01/FA
12/07/22  Aadi Bioscience, Inc.             8-K:5,9    12/06/22   11:355K                                   Donnelley … Solutions/FA
 9/22/22  Aadi Bioscience, Inc.             8-K:1,3,7,9 9/22/22   14:632K                                   Donnelley … Solutions/FA
 5/12/22  Aadi Bioscience, Inc.             10-Q        3/31/22   64:9.5M                                   ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             10-K       12/31/21   84:13M                                    ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             8-K:1,9     3/17/22   12:392K                                   Donnelley … Solutions/FA
11/10/21  Aadi Bioscience, Inc.             10-Q        9/30/21   76:12M                                    ActiveDisclosure/FA
 8/27/21  Aadi Bioscience, Inc.             8-K:1,2,3,5 8/26/21   26:11M                                    Donnelley … Solutions/FA
 5/17/21  Aadi Bioscience, Inc.             8-K:1,3,5,7 5/16/21    5:1.3M                                   Donnelley … Solutions/FA
 3/15/18  Aadi Bioscience, Inc.             10-K       12/31/17   74:8.6M                                   ActiveDisclosure/FA
Top
Filing Submission 0001628280-24-010901   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 6:09:54.3am ET